← All Signals

🏥 FDA: F.H. INVESTMENTS, Inc. (dba Asteria Health) — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-03-07Date

Summary

Estradiol pellet contamination expands Asteria Health's quality issues to hormone replacement products, potentially affecting women's health treatments. This broad contamination pattern suggests the company may face business closure or acquisition by regulators.

Actionable: Recommend healthcare providers switch to alternative estradiol suppliers immediately.

AI Confidence: 90%

Data Points

firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productESTRADIOL, 25 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-3025-32.

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now